Eli Lilly & Co. (LLY) News
Filter LLY News Items
LLY News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
LLY News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest LLY News From Around the Web
Below are the latest news stories about ELI LILLY & CO that investors may wish to consider to help them evaluate LLY as an investment opportunity.
Eli Lilly (NYSE:LLY) shareholders have earned a 44% CAGR over the last five yearsWhile Eli Lilly and Company ( NYSE:LLY ) shareholders are probably generally happy, the stock hasn't had particularly... |
FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – Will Insurance Cover This $1000-Per-Month Medication?The U.S. Food and Drug Administration (FDA) recently approved Zepbound® (tirzepatide) as the first prescription medication for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. Manufactured by Eli Lilly and Company, Zepbound offers a new approach to managing OSA symptoms while also promoting significant weight loss. What Is Zepbound? Zepbound is an injectable prescription medication created to help adults with obesity and weight-related problems, including obstruc |
Sector Update: Health Care Stocks Weaker Late AfternoonHealth care stocks were decreasing late Friday afternoon, with the NYSE Health Care Index down 0.6% |
AI, vaccine distrust, & the future of healthcare: Novartis CEOCan science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian Sozzi talks at length with Novartis (NVS) CEO Vas Narasimhan. Narasimhan has led the drug giant since 2018, doing deals that have expanded the company’s pipeline in areas like heart disease and cancer. Still, Narasimhan is feeling pressure to bring the investments to the bottom line to jumpstart its stock price. In the last year, Novartis shares have declined 6.69%. During that same timespan, the S&P 500 and Dow Jones Industrial Average have gained 22.8% and 12%, respectively. The iShares U.S. Healthcare ETF (IYH) is up slightly in the past year. The stock prices of Pfizer (PFE) and Moderna (MRNA) are down 8.5% and 61%, respectively in the past year. For full episo... |
Alzheimer’s Drugs Eyed as Next Big Obesity-Like Opportunity(Bloomberg) -- Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025.Most Read from BloombergWhat Robotaxis Brought San FranciscoNYC Condo Owners May Bear Costs of Landmark Green Building LawAmbitious High-Speed Rail Plans Advance in the Baltic RegionA Blueprint for Better Bike LanesNYC’s Subway Violence Deters Drive to Bring Workers Back to OfficeCompanies including Biogen Inc. and Eli Lilly & Co. h |
Trump Says World Is Free-Riding on U.S. Health Spending. He Has a Point.The president-elect might bring back efforts to make other countries pay more for drugs, but there are pitfalls. |
Eli Lilly (LLY) Vs Novo Nordisk (NVO): Which is the Best Weight Loss Stock for 2025?Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock. |
Is Eli Lilly and Company (LLY) the Best Blue Chip Stock to Buy for 2025?We recently published a list of 10 Best Blue Chip Stocks to Buy for 2025. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best blue chip stocks to buy for 2025. Both conservative and risk-tolerant investors favor blue chip stocks due to their […] |
Eli Lilly's Zepbound Can Now Be Covered by Medicare to Treat Sleep ApneaPopular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and Drug Administration approval last month. |
Medicare Will Pay for Zepbound for Some Patients. The Costs Could Be Huge.The government-funded insurance plan will now pay for the drug for patients with obstructive sleep apnea, a condition that afflicts many severely obese people. |